Exploring How Durvalumab Immunotherapy Targets Cancer Cells
Durvalumab, known commercially as Imfinzi, is revolutionizing cancer treatment with its innovative approach as an immune checkpoint inhibitor. By targeting the PD-L1 protein, it enhances the immune system’s ability to combat cancer cells, offering new hope for patients with advanced cancers. Explore its clinical trials, FDA approvals, and the future potential of this groundbreaking therapy. […]
3 minute read